PSMC4 promotes prostate carcinoma progression by regulating the CBX3–EGFR‐PI3K‐AKT‐mTOR pathway

Abstract

Proteasome 26S subunit ATPase 4 (PSMC4) could regulate cancer progression. However, the function of PSMC4 in prostate carcinoma (PCa) progression requires further clarification. In the study, PSMC4 and chromobox 3 (CBX3) levels were verified by TCGA data and tissue microarrays. Cell counting kit‐8, cell apoptosis, cell cycle, wound healing, transwell and xenograft tumour model assays were performed to verify biological functions of PSMC4 in PCa. RNA‐seq, PCR, western blotting and co‐IP assays were performed to verify the mechanism of PSMC4. Results showed that PSMC4 level was significantly increased in PCa tissues, and patients with PCa with a high PSMC4 level exhibited shorter overall survival. PSMC4 knockdown markedly inhibited cell proliferation, cell cycle and migration in vitro and in vivo, and significantly promoted cell apoptosis. Then further study revealed that CBX3 was a downstream target of PSMC4. PSMC4 knockdown markedly reduced CBX3 level, and inhibited PI3K‐AKT‐mTOR signalling. CBX3 overexpression markedly promoted epidermal growth factor receptor (EGFR) level. Finally, PSMC4 overexpression showed reverse effect in DU145 cells, and the effects of PSMC4 overexpression on cell proliferation, migration and clonal formation were rescued by the CBX3 knockdown, and regulated EGFR‐PI3K‐AKT‐mTOR signalling. In conclusion, PSMC4 could regulate the PCa progression by mediating the CBX3‐EGFR‐PI3K‐AKT‐mTOR pathway. These findings provided a new target for PCa treatment.

Exploring the therapeutic mechanism of curcumin in prostate cancer using network pharmacology and molecular docking

“…Mutations and expression of EGFR are associated with various types of cancers. Research has found that the downregulation of EGFR can significantly inhibit the proliferation, cell cycle, and migration of PCa cells in vitro and in vivo, and promote cell apoptosis [ 66 ]. It has been shown that using EGFR peptide-modified nanoparticles (NPs) as carriers to synergistically deliver doxorubicin (DTX) and pH-sensitive curcumin (CUR) prodrugs enables precision targeted therapy for prostate cancer.…”

CBX3 promotes clear cell renal carcinoma through PI3K/AKT activation and aberrant immunity

“…Several studies have highlighted the overactivation of the PI3K/AKT [ 14 ], which is linked to poorer clinical outcomes in patients with RCC [ 15 ]. Additionally, the potential for CBX3 to influence prostate cancer growth by modulating the PI3K/AKT pathway has been suggested [ 16 ]; however, the significance of the interplay of CBX3 with the PI3K/AKT pathway in ccRCC is unclear.…”